The global Immuno oncology drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027).  Cancer is the second biggest cause of mortality globally, following cardiovascular disease. According to research published by the World Health Organization (WHO) in 2018, cancer is responsible for 8.3 million mortalities each year, with 70% of new cancer cases likely to be recorded in the next 20 years. Further, Africa, Asia, Central and South America account for more than 60% of new cancer cases and 70% of cancer mortalities globally. The rise in the prevalence of cancer and the popularity of advanced therapies (biological and targeted pharmacological therapies) are driving the growth of the global immuno oncology drugs market. Furthermore, increased cancer awareness and early cancer screening contribute to the growth of the market. However, the high costs associated with new medication development, as well as the risk of failure and side effects associated with cancer treatment therapies, are hampering the growth of the market. 

Based on the therapeutic application, the market is segmented into breast cancer, melanoma, lung cancer, blood cancers, renal cell carcinoma, prostate cancer, bladder cancer, and other cancers. Among these, the breast cancer segment is expected to hold a major share in the market during the forecast period, owing to an increase in the number of people affected by the disease and the availability of early detection. On the other hand, the demand for immune-oncology drugs for lung cancer treatment is expected to grow at the fastest rate during the forecast period, owing to higher incidence, an increase in the geriatric population, changes in people's lifestyles, increase in tobacco smoking, passive smoking, which could lead to lung cancer. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Amgen Inc., AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Co., and Pfizer Inc.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Immuno Oncology Drugs Market Report by Segment

By Type

• Monoclonal Antibodies 

• Immune Checkpoint Inhibitors 

• Cancer Vaccines 

• Immune System Modulators 

• Others

By Therapeutic Application

• Breast Cancer 

• Melanoma

• Lung Cancer

• Blood Cancers

• Renal Cell Carcinoma

• Prostate Cancer

• Bladder Cancer

• Other Cancers

By End-User 

• Hospitals

• Clinics

• Ambulatory Surgical Centers

Global Immuno Oncology Drugs Market by Region